BR112019018861A2 - Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa - Google Patents

Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa

Info

Publication number
BR112019018861A2
BR112019018861A2 BR112019018861A BR112019018861A BR112019018861A2 BR 112019018861 A2 BR112019018861 A2 BR 112019018861A2 BR 112019018861 A BR112019018861 A BR 112019018861A BR 112019018861 A BR112019018861 A BR 112019018861A BR 112019018861 A2 BR112019018861 A2 BR 112019018861A2
Authority
BR
Brazil
Prior art keywords
prevent
nitrite
aqueous solution
myocardial infarction
sudden cardiac
Prior art date
Application number
BR112019018861A
Other languages
English (en)
Inventor
Craig Sherman
Original Assignee
Hope Medical Entpr Inc Dba Hope Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope Medical Entpr Inc Dba Hope Pharmaceuticals filed Critical Hope Medical Entpr Inc Dba Hope Pharmaceuticals
Publication of BR112019018861A2 publication Critical patent/BR112019018861A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa. são aqui fornecidos métodos para manter os níveis fisiológicos de nitrito em um sujeito em hemodiálise. também são aqui fornecidos métodos de administração de nitrito de sódio farmaceuticamente aceitável a um sujeito em hemodiálise.
BR112019018861A 2017-03-08 2018-03-06 Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa BR112019018861A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468857P 2017-03-08 2017-03-08
PCT/US2018/021053 WO2018165098A1 (en) 2017-03-08 2018-03-06 Intradialytic use of sodium nitrite

Publications (1)

Publication Number Publication Date
BR112019018861A2 true BR112019018861A2 (pt) 2023-10-10

Family

ID=63445965

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019018861A BR112019018861A2 (pt) 2017-03-08 2018-03-06 Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa

Country Status (14)

Country Link
US (4) US10328099B2 (pt)
EP (2) EP3592342B1 (pt)
JP (2) JP7314050B2 (pt)
KR (2) KR20240038812A (pt)
AR (1) AR111166A1 (pt)
AU (2) AU2018231016B2 (pt)
BR (1) BR112019018861A2 (pt)
CA (1) CA3055105A1 (pt)
IL (4) IL312092A (pt)
NZ (1) NZ756701A (pt)
PH (1) PH12019501950A1 (pt)
TW (2) TWI798203B (pt)
WO (1) WO2018165098A1 (pt)
ZA (2) ZA201905679B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3055105A1 (en) 2017-03-08 2018-09-13 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Intradialytic use of sodium nitrite
KR102647836B1 (ko) 2017-03-08 2024-03-15 호프 메디칼 엔터프라이즈스, 인크, 디비에이, 호프파마수으티칼즈 소듐 티오설페이트의 투석 중 용도
WO2021015235A1 (ja) * 2019-07-22 2021-01-28 学校法人北里研究所 透析装置

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341151C (en) 1985-09-10 2000-12-05 Elias Klein Osmotic agents form peritoneal dialysis
US6380163B1 (en) 1992-12-22 2002-04-30 Baxter International Inc. Peritoneal dialysis solutions with polypeptides
FI98538C (fi) 1993-10-20 1997-07-10 Enso Gutzeit Oy Menetelmä natriumhydroksidin valmistamiseksi valkolipeästä
US6306836B1 (en) 1994-01-21 2001-10-23 Baxter International Inc. Peritoneal dialysis solutions containing maltodextrins and amino acids
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
JP4882054B2 (ja) 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
JP5564158B2 (ja) * 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
US7547637B2 (en) * 2005-06-21 2009-06-16 Intel Corporation Methods for patterning a semiconductor film
US20090304600A1 (en) 2008-06-09 2009-12-10 Anupkumar Shetty Intradialytic administration of sodium thiosulfate
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120321724A1 (en) * 2009-06-15 2012-12-20 Bryan Nathan S Method of Measuring and Monitoring In Vivo Nitrite Levels
CA2767168C (en) 2009-07-08 2019-04-09 Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
AU2013212264B2 (en) 2012-01-23 2017-05-18 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to clostridium infections
JP5486069B1 (ja) 2012-11-05 2014-05-07 旭 酒井 透析装置
US20140350097A1 (en) 2013-05-23 2014-11-27 Medinox,Inc. Treatment of hypotension associated with hemodialysis
JP6183832B2 (ja) * 2013-06-19 2017-08-23 扶桑薬品工業株式会社 酸化ストレス抑制型透析用剤およびその調製方法
CA3055105A1 (en) 2017-03-08 2018-09-13 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Intradialytic use of sodium nitrite

Also Published As

Publication number Publication date
EP3592342A4 (en) 2020-12-23
IL268882B (en) 2021-07-29
IL301302B1 (en) 2024-05-01
TW201836594A (zh) 2018-10-16
WO2018165098A1 (en) 2018-09-13
IL312092A (en) 2024-06-01
IL284684A (en) 2021-08-31
CA3055105A1 (en) 2018-09-13
US12011456B2 (en) 2024-06-18
NZ756701A (en) 2022-07-01
TW202325265A (zh) 2023-07-01
JP2020510014A (ja) 2020-04-02
IL268882A (en) 2019-10-31
US20190255098A1 (en) 2019-08-22
US10328099B2 (en) 2019-06-25
PH12019501950A1 (en) 2020-06-15
ZA202208504B (en) 2024-01-31
TWI798203B (zh) 2023-04-11
US20230256005A1 (en) 2023-08-17
EP4406595A2 (en) 2024-07-31
AU2018231016A1 (en) 2019-09-19
KR20190130588A (ko) 2019-11-22
IL284684B2 (en) 2023-08-01
US10898512B2 (en) 2021-01-26
IL284684B1 (en) 2023-04-01
AU2018231016B2 (en) 2024-03-07
KR20240038812A (ko) 2024-03-25
US20180256637A1 (en) 2018-09-13
ZA201905679B (en) 2023-02-22
KR102647803B1 (ko) 2024-03-15
EP3592342B1 (en) 2024-06-19
US11564938B2 (en) 2023-01-31
JP2023134621A (ja) 2023-09-27
AU2024203535A1 (en) 2024-06-20
EP3592342A1 (en) 2020-01-15
IL301302A (en) 2023-05-01
TWI835595B (zh) 2024-03-11
JP7314050B2 (ja) 2023-07-25
US20210077524A1 (en) 2021-03-18
AR111166A1 (es) 2019-06-12

Similar Documents

Publication Publication Date Title
CO2018005854A2 (es) Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos
DOP2015000300A (es) Compuestos de pirimidinodiona contra estados cardíacos
BR112019018861A2 (pt) Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa
BR112017017888A2 (pt) derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes
GB2540638A8 (en) Compositions, Formulations and methods for treating ocular diseases
PE20142363A1 (es) Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
BR112015004012A2 (pt) combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
CL2021001389A1 (es) Formulaciones en cápsula
BR112015004643A2 (pt) métodos e composições para ressucitação hipotensiva
BR112018013408A2 (pt) derivados de c-glicosídeo que têm anel fenila fusionado ou sais farmaceuticamente aceitáveis dos mesmos, método para preparar os mesmos e composição farmacêutica compreendendo os mesmos
BR112022001645A2 (pt) Artigo configurado para liberação de um agente terapêutico, e, métodos para distribuir fármaco intestinal e para administrar um agente terapêutico
BR112015024897A2 (pt) derivado de fenila
CN104083353B (zh) N-乙酰半胱氨酸在制备预防快速上浮脱险致减压病的药物中的应用
RU2015133365A (ru) Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно
RU2016147455A (ru) Способ лечения кожных проявлений склеродермии
MX2018001041A (es) Concentrado que contiene alprostadil.
Altin IgE-mediated allergic angioedema in an elderly patient: case report
UA94690U (en) Method of preparation the patients with concomitant coronary heart disease to video thoracoscopic operations
Akgullu Myocardial infarction secondary to Kounis Syndrome: case report
Athar Dobutamine/norepinephrine
UA97450U (en) Method of fetal neuroprotection

Legal Events

Date Code Title Description
B12F Other appeals [chapter 12.6 patent gazette]